104
Participants
Start Date
March 6, 2025
Primary Completion Date
March 31, 2027
Study Completion Date
March 31, 2027
Efanesoctocog alfa
Treatment starts when the patient completes the parent study and continues until efanesoctocog alfa is commercially available in each patient's respective country, or until March 2027, whichever comes first.
NOT_YET_RECRUITING
Sobi Investigational Site, Plovdiv
NOT_YET_RECRUITING
Sobi Investigational Site, Sofia
NOT_YET_RECRUITING
Sobi Investigational Site, Bordeaux
NOT_YET_RECRUITING
Sobi Investigational Site, Brest
NOT_YET_RECRUITING
Sobi Investigational Site, Bron
NOT_YET_RECRUITING
Sobi Investigational Site, Le Kremlin-Bicêtre
NOT_YET_RECRUITING
Sobi Investigational Site, Lille
NOT_YET_RECRUITING
Sobi Investigational Site, Marseille
NOT_YET_RECRUITING
Sobi Investigational Site, Strasbourg
NOT_YET_RECRUITING
Sobi Investigational Site, Athens
NOT_YET_RECRUITING
Sobi Investigational Site, Catanzaro
NOT_YET_RECRUITING
Sobi Investigational Site, Florence
RECRUITING
Sobi Investigational Site, Milan
NOT_YET_RECRUITING
Sobi Investigational Site, Milan
RECRUITING
Sobi Investigational Site, Naples
NOT_YET_RECRUITING
Sobi Investigational Site, Parma
NOT_YET_RECRUITING
Sobi Investigational Site, Rome
NOT_YET_RECRUITING
Sobi Investigational Site, Vicenza
NOT_YET_RECRUITING
Sobi Investigational Site, Oslo
RECRUITING
Sobi Investigational Site, A Coruña
RECRUITING
Sobi Investigational Site, Zaragoza
RECRUITING
Sobi Investigational Site, Lund
Lead Sponsor
Collaborators (1)
PSI CRO
INDUSTRY
Swedish Orphan Biovitrum
INDUSTRY